Is a plan to use androgen deprivation therapy associated with higher baseline cardiovascular risk in men with prostate cancer?
The apparent association between planned androgen deprivation therapy and cardiovascular risk in prostate cancer patients is driven by confounding baseline risk factors rather than the therapy plan itself.
Two-thirds of men with prostate cancer are at high cardiovascular risk. There is a positive association between a plan to use androgen deprivation therapy and baseline cardiovascular risk factors. However, this association is explained by confounding factors.
Leong et al. (Fri,) studied this question.